Skip to main content
Log in

Treatment of Mild, Moderate, and Severe Lupus Erythematosus: Focus on New Therapies

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Despite large-scale efforts devoted to the conduct of clinical trials in systemic lupus erythematosus (SLE), no new therapy has been approved for treatment of this disease in more than 50 years. Increased understanding of the immunologic mechanisms underlying SLE has led to the development of a variety of biologic agents that target specific aspects of the adaptive and innate arms of the immune system, including B cells, T cells, dendritic cells, and various cytokines. One of these agents, belimumab, was the subject of two positive phase 3 trials in nonrenal lupus that have given us hope that a new therapy for SLE may be finally within our grasp. In addition to these newer therapies, recent studies of standard-of-care medications such as mycophenolate mofetil and hydroxychloroquine have better defined the efficacy and safety of these agents for the treatment of lupus nephritis and nonrenal lupus. This article provides a discussion of several novel biologic agents at different stages of development for the treatment of SLE, as well as an analysis of newer data on agents that have been used in the treatment of SLE for many years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. •• Mackay F, Figgett WA, Saulep D, et al. B-cell stage and context-dependent requirements for survival signals from BAFF to the B-cell receptor. Immunol Rev 2010, 237:205–25. This is a very detailed review of the role of BAFF in B-cell development, survival, and activation.

    Article  PubMed  CAS  Google Scholar 

  2. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003;48:1484–92.

    Article  PubMed  CAS  Google Scholar 

  3. Merrill JT, Newelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus. Arthritis Rheum. 2010;62:222–33.

    Article  PubMed  CAS  Google Scholar 

  4. Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 2009;60:S429 [abstract 1149].

    Google Scholar 

  5. Terrier B, Amoura A, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French Autoimmunity to Rituximab Registry. Arthritis Rheum. 2010;62:2458–66.

    Article  PubMed  CAS  Google Scholar 

  6. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first 50 patients. Arthritis Care Res. 2009;61:482–7.

    Article  Google Scholar 

  7. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patient with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28:468–76.

    PubMed  CAS  Google Scholar 

  8. •• Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 2010, 29: 707–16. This is a systematic review of results of off-label use of rituximab for autoimmune disease.

    Article  PubMed  Google Scholar 

  9. Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008;67 Suppl 3:iii64–5.

    Article  PubMed  Google Scholar 

  10. Furie RA, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R109.

    Article  PubMed  Google Scholar 

  11. Wallace DJ, Stohl W, Furie RA, et al. A phase II randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–78.

    Article  PubMed  CAS  Google Scholar 

  12. Navarra S, Guzman R, Gallacher A, et al. Belimumab, a BLys-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. American College of Rheumatology 2009 Annual Scientific Meeting: Philadelphia, PA (17–21 October, 2009)

  13. Furie RA, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through week 76. American College of Rheumatology 2010 Annual Scientific Meeting: Atlanta, GA (6–10 November, 2010)

  14. Merrill JT, Wallace DJ, Furie RA, et al. Five-year experience with belimumab, a BLyS-specific inhibitor, in patients with systemic lupus erythematosus (SLE). American College of Rheumatology 2010 Annual Scientific Meeting: Atlanta, GA (6–10 November, 2010)

  15. Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74–85.

    Article  PubMed  Google Scholar 

  16. Wallace DJ, Kalunian KC, Petri MA, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEM, a phase IIb study. Arthritis Rheum. 2010;62:S605 [Abstract 1452].

    Article  Google Scholar 

  17. Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56:4142–50.

    Article  PubMed  Google Scholar 

  18. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus. Arthritis Rheum. 2010;62:3077–87.

    Article  PubMed  CAS  Google Scholar 

  19. •• Crow MK. Interferon-alpha: a therapeutic target in systemic lupus erythematosus. Rheum Dis Clin N Am 2010, 36: 173–86. This is an outstanding overview of the immunobiology of IFN-α and its role in autoimmune diseases.

    Article  Google Scholar 

  20. Niewold TN, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulemic vasculitis associated with hepatitis C. Clin Rheumatol. 2005;24:178–81.

    Article  PubMed  Google Scholar 

  21. Hooks JJ, Moutsopoulos HM, Geis SA, et al. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979;301:5–8.

    Article  PubMed  CAS  Google Scholar 

  22. Crow MK, Kirou KA, Wohlgemuth J. Microarray analysis of interferon-regulated genes in SLE. Autoimmunity. 2003;36:481–90.

    Article  PubMed  CAS  Google Scholar 

  23. Niewold TB, Clark DN, Salloum R, et al. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:948364.

    Article  PubMed  Google Scholar 

  24. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1785–96.

    Article  PubMed  CAS  Google Scholar 

  25. McBride JM, Morimoto A, Drappa J. Genentech’s rontalizumab is well-tolerated by lupus patients in a phase I clinical trial. Lupus Foundation of America Website, accessed 11/28/2010. Available at http://www.lupus.org/webmodules/webarticlesnet/templates/new_empty.aspx?articleid=2844&zoneid=76

  26. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156–62.

    Article  PubMed  CAS  Google Scholar 

  27. Chan TM, Tse KC, Tang CS, et al. Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076–84.

    Article  PubMed  CAS  Google Scholar 

  28. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353:2219–28.

    Article  PubMed  CAS  Google Scholar 

  29. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.

    Article  PubMed  CAS  Google Scholar 

  30. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology. 2010;49:128–40.

    Article  PubMed  Google Scholar 

  31. Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77:152–60.

    Article  PubMed  CAS  Google Scholar 

  32. Wofsy D, et al. Aspreva lupus management study maintenance results. Lupus 2010; 19 (Abstr. Suppl): 27 (Abstract CS12.5)

  33. Houssiau FA, D’Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial. Ann Rheum Dis 2010 (Epub ahead of print)

  34. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med. 1991;324:150–4.

    Article  Google Scholar 

  35. The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus. 1998;7:80–5.

    Article  Google Scholar 

  36. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum. 2006;54:3068–70.

    Article  PubMed  CAS  Google Scholar 

  37. Wallace DJ. Antimalarial therapies. In: Wallace D, Hahn B, editors. Dubois’ lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1152–74.

    Google Scholar 

  38. Barrat FJ, Meeker T, Gregorio J, et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005;202:1131–9.

    Article  PubMed  CAS  Google Scholar 

  39. •• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69: 20–8. This is a comprehensive, systematic review of the role of antimalarials in disease activity, damage, and toxicity related to SLE.

    Article  PubMed  CAS  Google Scholar 

  40. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res. 2010;62:775–84.

    Article  CAS  Google Scholar 

  41. •• Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/LA antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010:69: 1827–30. This was an expertly performed study combining outcomes of three cohorts of infants born to mothers with SLE and anti-SSA/SSB antibodies.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Dr. Dall’Era has served as an investigator for clinical trials sponsored by Genentech, EMD Serono, and Human Genome Sciences.

Dr. Chakravarty has served as an investigator for clinical trials sponsored by Genentech, EMD Serono, and Human Genome Sciences, and as a consultant for Genentech.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eliza F. Chakravarty.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dall’Era, M., Chakravarty, E.F. Treatment of Mild, Moderate, and Severe Lupus Erythematosus: Focus on New Therapies. Curr Rheumatol Rep 13, 308–316 (2011). https://doi.org/10.1007/s11926-011-0186-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0186-6

Keywords

Navigation